Hospital  Central Radiology Division 

Research Interests 【 display / non-display

  • SABR

  • SBRT

  • Brachytherapy

  • Radiation Oncology

  • Interventional Radiology

display all >>

Graduating School 【 display / non-display

  • 2008.04

    Akita University   Faculty of Medicine   Graduated

Graduate School 【 display / non-display

  • 2019.04

    Akita University  Graduate School, Division of Medicine  Doctor's Course  Completed

Degree 【 display / non-display

  • Akita University -  Degree of the doctorate in Medical Science

Campus Career 【 display / non-display

  • 2022.05

    Akita University   Hospital   Central Radiology Division   Assistant Professor  


Thesis for a degree 【 display / non-display

  • Safety and Treatment Outcomes of Stereotactic Body Radiotherapy for Pulmonary Tumors : A Retrospective Single-Center Study

    Satoshi Kumagai, Yuki Wada, Akira Anbai, Noriko Takagi, Eriko Okuyama, Manabu Hashimoto 

    秋田医学  48 ( 3-4 ) 85 - 98   2022.03  [Refereed]

    Domestic Co-author

    Stereotactic body radiotherapy (SBRT) uses hypofractionated and more precise irradiation methods, and has the advantages of shorter duration, better outcomes, and fewer side effects than conventional radiotherapy. However, the optimal dosage remains unclear. The purpose of the study was to analyze our preliminary treatment results and safety. We retrospectively analyzed 32 patients (primary cancer, 22; metastatic cancer, 10) who underwent SBRT for pulmonary tumors at our hospital from April 2015 to June 2020. SBRT was performed with escalated dose prescriptions (up to 55Gy in 4 fractions/64Gy in 8 fractions for peripheral/central lesions, respectively). We evaluated the local control rate (LC rate), overall survival (OS), progression-free survival (PFS), disease-specific survival (DSS), and adverse events. The target lesions comprised 22 primary lung cancers and 13 metastatic lung cancers. The 2-year LC, OS, PFS, and DSS rates were 82.5%, 68.3%, 50.5%, and 88.0% for primary lung cancer patients and 83.1%, 29.9%, 23.1%, and 48.6% for metastatic lung cancer patients, respectively. Five cases of radiation pneumonitis of grade 2 or higher, one of grade 1 dermatitis and 1 of esophagitis were observed as adverse events. We showed that the treatment outcomes of SBRT for primary and metastatic lung cancers were mostly acceptable.